Request a Quotation

Your Contact Information
Peptides Logo
Support and counselling under:
+49(0)3302 - 2022000 info@peptides.de
€0.00*
Structure of gp100 (pmel17) 476-485 (HLA-A*02:01)
Logo for Cancer
Cancer

gp100 (pmel17) 476-485 (HLA-A*02:01) VLYRYGSFSV

€105.00*

Prices excl. VAT plus shipping costs
Available, delivery time: 3 weeks
sterile and endotoxin free
Delivery Format: The product is supplied freeze dried.
Purity: 95% HPLC-MS
Caution: For research use only. Not for use in humans.
Amount in mg
1
Add to Cart
Product number: EP11184_1

Description

The peptide gp100 (pmel17) 476-485 (HLA-A*02:01) with the amino acid sequence VLYRYGSFSV is a linear peptidic epitope (epitope ID 69906) studied as part of Melanocyte protein PMEL (UniProt:P40967) from Homo sapiens (human).

gp100 (pmel17) 476-485 (HLA-A*02:01) has been studied for immune reactivity in publications and has been tested in T cell assays and MHC ligand assays.

TechData

Sequence: VLYRYGSFSV
Gene: PMEL
Delivery: 3 weeks
C-Terminus: OH
N-Terminus: H
Amount: 1 mg
Counterion: TFA
Protein: Melanocyte protein PMEL
Species: Human
Allele: HLA-A*02:01
Application: Flow Cytometry
Indication: Cancer
Purity: 95% HPLC-MS

Documents

Material data sheet Safety data sheet Storage and handling of peptides Probing of membranes with HRP
Skip product gallery

More gp100 peptides

gp100 154-162 (HLA-A*02:01)
gp100 154-162 (HLA-A*02:01)
KTWGQYWQV is a linear peptidic epitope (epitope ID 33915) studied as part of Melanocyte protein PMEL from Homo sapiens (human). This epitope has been studied for immune reactivity, tested in T cell assays, B cell assay and MHC ligand assays

From €105.00*
Details
gp100 17-25 (HLA-A*03:01)
gp100 17-25 (HLA-A*03:01)
The peptide gp100 17-25 (HLA-A*03:01) with the amino acid sequence ALLAVGATK is a linear peptidic epitope (epitope ID 2688) studied as part of Melanocyte protein PMEL (UniProt:P40967) from Homo sapiens (human).gp100 17-25 (HLA-A*03:01) has been studied for immune reactivity in publications and has been tested in T cell assays and MHC ligand assays.

From €105.00*
Details
gp100 170-178 (HLA-A*24:02)
gp100 170-178 (HLA-A*24:02)
The peptide gp100 170-178 (HLA-A*24:02) with the amino acid sequence VYFFLPDHL is a linear peptidic epitope (epitope ID 1075826).The epitope is an unspecified neo-epitope of: Melanocyte protein PMEL from Homo sapiens (human) Melanocyte protein PMEL.The epitope is an unspecified neo-epitope of: melanoma antigen gp100 from Homo sapiens (human) melanoma antigen gp100.gp100 170-178 (HLA-A*24:02) has been studied for immune reactivity in publications and has been tested in T cell assays and MHC ligand assay.

From €105.00*
Details
gp100 209-217 (HLA-A*02:01)
gp100 209-217 (HLA-A*02:01)
ITDQVPFSV is a linear peptidic epitope studied as part of Melanocyte protein PMEL from Homo sapiens (human) and Melanocyte protein PMEL from Mus musculus (mouse). Gp 100 209-217 peptide ITDQVPFSV (HLA-A*02:01) for stimulation of T-cells. Single peptide (ITDQVPFSV) for stimulation of human Gp 100-specific CD8+ T-cells.

From €105.00*
Details
gp100 209-217 mutant (HLA-A*02:01) 210M
gp100 209-217 mutant (HLA-A*02:01) 210M
gp100 209-217 Pos. 210M (HLA-A*02:01) IMDQVPFSV is a linear peptidic epitope studied as part of Melanoma antigen preferentially expressed in tumors from Homo sapiens (human). This epitope has been studied for immune reactivity in several publication, tested in T cell assays and MHC ligand assays. This modified gp100 peptide amino acids 209 to 217 is a MHC-associated HLA-A2.1-restricted epitope derived from melanoma antigene. It can be processed, presented, and recognized by T cells. Alteration of the gp100 209-217 peptide to gp100 209-217 Met2 at the second amino acid changing threonine to a methionine was found to increase the affinity for MHC-associated HLA-A2.1 resulting in enhanced induction of T cells reactive to native gp100

From €105.00*
Details
gp100 280-288 (HLA-A*02:01)
gp100 280-288 (HLA-A*02:01)
YLEPGPVTA is a linear peptidic epitope studied as part of Melanocyte protein PMEL from Homo sapiens (human). gp100 peptide YLEPGPVTA (HLA-A*02:01)ï¾  for stimulation of human gp100-specific CD8+ T-cells. The peptide is synthesised as it is presented by the MHC class I HLA-A*0201 allele.

From €105.00*
Details
gp100 280-288 mutant (HLA-A*02:01) 288V
gp100 280-288 mutant (HLA-A*02:01) 288V
Antigen Peptide gp100 280-288 mutant (HLA-A*02:01) 288V YLEPGPVTV for stimulation of antigen-specific T cells in T cell assays such as ELISPOT, ICS, cytotoxity or proliferation assays.

From €105.00*
Details
This website uses cookies to ensure the best experience possible. More information...